More than 400 Chinese products will be temporarily exempted from tariffs that President Donald Trump's administration imposed last year.China Economyread more
Apple will get a taste of whether upgraded features on the new iPhone 11 are enough to lure shoppers to retail stores around the world as the new smartphones officially hit...Technologyread more
As tensions might drag over the next decade, investors have to learn to operate under prolonged uncertainty, said Warburg Pincus' Charles Kaye.World Economyread more
U.S. Vice President Mike Pence on Thursday struck an unyielding tone on America's position in its trade war with China.Delivering Alpharead more
Billionaire investor Howard Marks, the co-chairman of Oaktree Capital, predicts there won't be a recession in the U.S. for another two years.US Economyread more
Network officials also said voters should expect more of a Koch focus on grassroots activism throughout the 2020 election cycle.Politicsread more
One person was killed and five others wounded on Thursday in a shooting on the streets of Washington, D.C., not far from the White House, police said.U.S. Newsread more
Stores are extending hours and cities are spending on light shows as China tries to encourage consumers to spend more money at night.China Economyread more
New research suggests fewer girls pursue careers in STEM — science, technology, engineering and math — because they're better than boys at reading.Closing The Gapread more
Stocks in Asia Pacific edged up on Friday as investors digested a series of developments overnight on the U.S.-China trade front that dampened hopes of a deal being reached...Asia Marketsread more
GM's usage of temporary workers, potential closure of plants and health care contributions remain major sticking points, according to people familiar with the talks.Autosread more
It's that time again! Jim Cramer rang the lightning round bell, which means he gave his take on caller favorite stocks at rapid speed:
Bristol-Myers Squibb: "Bristol-Myers, we own a small position for the charitable trust. It is our smallest position, we do believe the stock will go lower. When it yields about 3.5 percent, and it yields 3 right now, maybe we pull the trigger and buy a little more. But not yet, the drug stocks are headed lower."
KKR & Co: "No, the dividend is not secure because it's now meant to fluctuate with the assets that they want to sell. And frankly, that is not an optimal situation for me. I would not make a big bet right here on KKR, because we don't know what they are up to."
Yum Brands: "No we are not holding or selling, we are a buyer of Yum Brands because the split is going to be good. They are going to turn a lot of capital and we have to think that this is just a great idea. A fast core from China, the rest of the world not as good but maybe give you a bigger dividend. Greg Creed [CEO] is doing it dead right."
Transocean Ltd: "I don't like Transocean because I don't like deep water. You've got Baker Hughes, you've got Halliburton. Those are better."
Insys Therapeutics: "This is a roll of the dice, 61 percent down, cancer therapeutic. Many of these stocks do not work out, but if you want to speculate, I'll bless it. Although I'm not crazy about it."
Monster Beverage Corp: "I have been a long-term supporter of Monster because they are taking share from the other guys and it is a very well-run company. But I'm not pressing it right now. The one I like to pound the table is Constellation Brands."
Sarepta Therapeutics: "I think that trade has come and gone and you should ring the register."
Scotts Miracle-Gro Co: "Scotts Miracle-Gro has been a winner right here, but I say be careful. We are a little late in the cycle for this one."